Nyhet -

Find out: Why bridge the existing gap between biochemical and cell based assays?

Discover the Attana Cell 200: label-free cell based QCM biosensor for efficient drug candidate selection- performing both biochemical and cell based assays!

The Attana Cell 200 has the unique ability to disclose the full binding profile, providing biologically relevant determination of kinetic rate constants, affinity and off-target interactions directly on cell surface, thus bridging the gap between traditional biochemical biosensors and cell based assays.

Why bridge the existing gap between biochemical and cell based assays?
One efficient tool in the selection process is biochemical label-free kinetic characterisation of interactions between candidate and target molecules. Information on association and dissociation rates and affinity is provided under purified conditions. However, the results obtained are often different compared to the affinity results obtained with cell based methods (see fig below).

Hence, there is an uncertainty in the data used in the selection process.
The reason for the discrepancy is due to several factors, one being the difference in assay conditions. A biochemical assay is performed under artificial purified conditions whereas a cell based assay is performed under biological relevant conditions but usually with labelled molecules limited to end point and equilibrium data. The difference in kinetic performance between biochemical and cell based assays is clearly seen in figure here, explaining the difference in affinity. The main reason being that the association and dissociation rate are affected by clustering and accessibility hindrance of the targets on the cells, in contrast to the artificial perfect conditions in the biochemical assays.

Off-target interactions, interaction with other targets or the cell membrane in its self can be as important as the kinetic and affinity data and can severely affect the distribution of the candidates.

Bridging the gap between biochemical and cell based assays enables an early and efficient selection process in developing new therapeutics and diagnostics.

The Attana Cell 200 has the unique ability to disclose the full binding profile under biologically relevant conditions thereby bridging the gap between traditional biochemical biosensors and cell based assays.


Relaterade länkar

Ämnen

  • Vetenskap, teknik

Kategorier

  • attana
  • attana cell 200
  • biosensor
  • bridge the gap
  • cell based assays
  • biochemical assays
  • kinetics
  • qcm

Relaterad media

Relaterat innehåll

  • Biosensor- Attana Cell 200, label free, real time kinetics on cells

    Revolutionary Swedish invention can potentially improve drug development! Attana AB introduces the Attana Cell 200 – the first system to permit real-time kinetic analysis of molecular interactions directly on cell surfaces, bringing drug development a step closer to the body.

  • En ny Generation av Cell-Biosensorer för cancer-forskning

    Läs artikeln i det senaste numret av  IPT (Innovations in Pharmaceutical technologies) om nya generationens cell-biosensorer som möjliggör studier  av molekylära interaktioner direkt på celler och på så sätt indikerar rätt läkemedelskandidater i ett tidigare skede inför bland annat cancer-forskning. Att få fram en bra biologiskt anpassad modell som denna med hjälp av en cell-biosensor minskar kost

  • A New Generation of Cell-Biosensors targeting Cancer

    Read the latest article in IPT (Innovations in Pharmaceutical Technology) about the new generation cell-biosensors that enables studies in a more relevant cellular environment to better understand drug-cell interactions for development of new pharmaceuticals. A model like this using bio-sensors could significantly reduce the costs and time-scales involved in the development of the next generation

  • Attana in Swedish Life Sciences

    Swedes are well known to be innovative and building successful global companies and international brands. In Swedish Life Sciences many of the Swedish companies representing the entire health care spectrum are compiled and presented, there among Attana AB.

Relaterade event

Fyll i din epostadress för att följa Attana AB

När du väljer att skapa ett konto och följa ett nyhetsrum kommer dina personuppgifter behandlas av oss och av ägaren av nyhetsrummet för att du ska kunna motta nyheter och uppdateringar enligt dina bevakningsinställningar.

För att läsa mer om detta, var vänlig läs vår Integritetspolicy som berör vår behandling av dina personuppgifter, och Integritetspolicy för Contacts som berör behandlingen av dina personuppgifter från ägaren av nyhetsrummet du följer.

Vänligen notera att våra Användarvillkor gäller alla våra tjänster.

Du kan dra tillbaka ditt samtycke när som helst genom att avregistrera dig eller genom att ta bort ditt konto.
Kolla din inkorg

Mejl skickat till __email__. Klicka på länken i mejlet för att följa Attana AB.

Okej